Literature DB >> 4730880

Preliminary studies on the pharmacology of an antidysrhythmic, Kö 1173, in man.

M A Kiddie, R B Royds, T R Shaw.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4730880      PMCID: PMC1776298     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  1 in total

1.  The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias.

Authors:  J D Allen; J M Ekue; R G Shanks; S A Zaidi
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

  1 in total
  7 in total

1.  The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH.

Authors:  M A Kiddie; C M Kaye
Journal:  Br J Clin Pharmacol       Date:  1974-02       Impact factor: 4.335

2.  The influence of urinary pH on the elimination of mexiletine.

Authors:  M A Kiddie; C M Kaye; P Turner; T R Shaw
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

3.  A rapid method for the determination of plasma mexiletine levels by gas chromatography.

Authors:  I D Bradbrook; C James; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 6.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

7.  Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

Authors:  P Lledó; S M Abrams; A Johnston; M Patel; R M Pearson; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.